glp-1 blue cross Blue Shield to stop covering popular weight-loss drugs GLP-1 | Blue Cross and

While Wegovy and Zepbound added non-weight-loss indications, this second payer, instead, moved to outright rejecting claims between 70% and 80% of the time

Experiencing mucus in stool while taking tirzepatide

These recommendations are based on their potential benefits and how they can complement GLP-1 therapy to enhance health outcomes

Different weight regain was observed in subjects with different characteristics

The FDA says these are not approved or tested by the FDA

Almost one-third (31%) of all patients dispensed the drugs in 2023 had no recorded diagnosis of either diabetes or obesity, compared to 8% in 2019